Schedule of Accreditation

issued by

United Kingdom Accreditation Service

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Unit 9, Meridian Business Park

Fleming Road

EN9 3BZ

Waltham Abbey



8771

Accredited to ISO/IEC 17025:2017

Matrix Diagnostics Limited


Issue No: 020 Issue date: 07 January 2025


Contact: Mrs Andrea Blowers Tel: +44 (0) 1604 271387 E-Mail: a.blowers@matrixdiagnostics.co.uk Website: www.matrixdiagnostics.co.uk


Testing performed at the above address only

DETAIL OF ACCREDITATION

DETAIL OF ACCREDITATION				
Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used		
BODY FLUIDS	Workplace Drugs Analysis	Documented In-House Methods:		
Urine (unpreserved)	Adulteration tests: pH Creatinine Specific Gravity	MATLSOP027using CEDIA immunoassay and Beckman Coulter AU680 and AU480 detection		
Urine (unpreserved)	Presumptive screening for the presence of the following drugs or drug groups (cut-off): 6-MAM (10ng/ml) Amphetamines (Including Methamphetamines) (300ng/ml) Barbiturates (200ng/ml) Benzodiazepines (200ng/ml) Buprenorphine (5ng/ml) Cannabis (50ng/ml) Cocaine (150ng/ml) EDDP (100ng/ml) Ethyl-Alcohol (107,67,40,39,20 ng/ml) Ketamine (100ng/ml) LSD (0.5ng/ml) Methaqualone (300ng/ml) Opiates (300ng/ml) Phencyclidine (25ng/ml) Propoxyphene (300ng/ml) Tramadol (200ng/ml)	MATLSOP027 using CEDIA immunoassay and Beckman Coulter AU680 and AU480 detection		







	Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK					
ESTING 8771 Accredited to ISO/IEC 17025:2017		Matrix Diagnostics Limited Issue No: 020 Issue date: 07 January 2025				
Testing performed at main address only						
Materials/Products tes	ted	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used			
BODY FLUIDS (cont'd)		Workplace Drugs Analysis (cont'd)	Documented In-house methods			
Oral fluid (Extracted from the Intercep collection device)	ot i2he™	Presumptive screening for the presence of the following drugs or drug groups (Cut-off): Amphetamine (40ng/ml) Methamphetamine (40ng/ml) Benzodiazepines (10ng/ml) Cocaine (30ng/ml) Cannabis (10ng/ml) Opiates (40ng/ml) 6-MAM (4ng/ml) Methadone (50ng/ml) Buprenorphine (5ng/ml)	MATLSOP014 using CEDIA immunoassay and Beckman Coulter AU680 Detection			
Oral fluid (Extracted from the Intercep collection device)	ot 2	Presumptive Screening and Confirmation (above specified cut- off limit) and Quantitaion of the following drugs (cut-off limit);[Concentration Range]	MATLSOP049 and MLEQ71 using Waters Xevo TQ-S LCMSMS			
		Tetrahydrocannabinol [THC] (2ng/ml); [0.5-80ng/ml]				
Oral fluid (Extracted from the Intercep collection device)	ot i2he™	Presumptive Screening and Confirmation (above specified cut- off limit) and Quantitaion of the following drugs (above specified cut-off limit/s) [concentration range]	MATLSOP064 and MLEQ71 using using solid phase extraction and LCMS/MS analysis (Waters Xevo TQS micro)			
		Opiate Group: (8; 15 ng/ml); [5 – 200 ng/ml] Codeine Dihydrocodeine Morphine (2ng/ml);[0.8-30ng/ml] 6-MAM				
		Buprenorphine Group: (1 ng/ml); [0.8-30 ng/ml] Buprenorphine				

UKAS TESTING 8771		Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK			
		Matrix Diagnostics Limited Issue No: 020 Issue date: 07 January 2025			
Accredited to ISO/IEC 17025:2017					
Testing performed at main address only					
Materials/Products tes	ted	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used		
BODY FLUIDS (cont'd)		Workplace Drugs Analysis (cont'd)	Documented In-house methods		
Oral fluid (Extracted from the Intercep collection device)	t i2he™	Presumptive Screening and Confirmation (above specified cut- off limit) and Quantitaion of the following drugs (cut-off limit);[Concentration Range]	MATLSOP064 and MLEQ71 using using solid phase extraction and LCMS/MS analysis (Waters Xevo TQS micro)		
		Methadone Group: (4; 20 ng/ml); [2-80 ng/ml] EDDP Methadone			
		Cocainics Group: (8 ng/ml); [2-80 ng/ml] AEME (1.6; 8 ng/ml); [0.8 – 80 ng/ml] Benzoylecgonine (8.0 ng/ml); [0.8 – 80 ng/ml] Cocaine			
		Ketamine Group: (1.6; 8 ng/ml);[0.8-80 ng/ml] Ketamine			
		Amphetamine Group: (6; 15 ng/ml); [5-200 ng/ml] Amphetamine MDA MDEA MDMA Methamphetamine			
		Benzodiazepine Group: (2; 3ng/ml); [0.8-30ng/ml] Diazepam Nordiazepam Oxazepam Temazepam (3ng/ml); [0.8-30ng/ml] Lorazepam			

	Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK			
B771 Accredited to ISO/IEC 17025:2017	Matrix Diagnostics Limited Issue No: 020 Issue date: 07 January 2025			
	Testing performed at main address only			
Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used		
	Cathinone Group: (6; 30ng/ml); [5-200ng/ml] Cathinone Mephedrone Methcathinone MDPV			
BODY FLUIDS (cont'd) Oral fluid (Extracted from the Intercept i2he collection device)	 Workplace Drugs Analysis (cont'd) Presumptive Screening and Confirmation (above specified cut- off limit) and Quantitaion of the following drugs (cut-off limit);[Concentration Range] Tramadol Group: (4; 20 ng/ml); [2-80ng/ml] Tramadol Gabapentinoid Group: (4; 20 ng/ml); [2-80 ng/ml] Gabapentin Pregabalin 	Documented In-house methods MATLSOP064 and MLEQ71 using using solid phase extraction and LCMS/MS analysis (Waters Xevo TQS micro)		
END				